Allena Pharmaceuticals, Inc. ALNA
We take great care to ensure that the data presented and summarized in this overview for Allena Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ALNA
Top Purchases
Top Sells
About ALNA
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Insider Transactions at ALNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2021
|
Louis Md Brenner President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,582
+27.63%
|
-
|
|
Nov 15
2021
|
Louis Md Brenner President and CEO |
SELL
Open market or private sale
|
Direct |
40,328
-12.26%
|
$0
$0.81 P/Share
|
|
May 10
2021
|
Louis Md Brenner President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
83,721
+26.81%
|
-
|
|
May 10
2021
|
Louis Md Brenner President and CEO |
SELL
Open market or private sale
|
Direct |
25,215
-11.03%
|
$25,215
$1.11 P/Share
|
|
Dec 17
2020
|
Louis Md Brenner President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
247,932
+50.0%
|
-
|
|
Dec 17
2020
|
Louis Md Brenner President and CEO |
SELL
Open market or private sale
|
Direct |
103,116
-41.59%
|
$103,116
$1.36 P/Share
|
|
Dec 17
2020
|
Edward Wholihan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
164,822
+46.48%
|
-
|
|
Dec 17
2020
|
Edward Wholihan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
68,550
-36.11%
|
$68,550
$1.36 P/Share
|
|
Nov 06
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
215,000
+7.15%
|
$3,010,000
$14.0 P/Share
|
|
Nov 06
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,575,964
+50.0%
|
-
|